Revvity, Inc. (NYSE:RVTY) Shares Bought by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD increased its position in shares of Revvity, Inc. (NYSE:RVTY - Free Report) by 17.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 7,631,597 shares of the company's stock after acquiring an additional 1,151,821 shares during the quarter. Price T Rowe Associates Inc. MD owned approximately 6.27% of Revvity worth $851,764,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Assetmark Inc. lifted its holdings in shares of Revvity by 3,700.0% during the 4th quarter. Assetmark Inc. now owns 266 shares of the company's stock worth $30,000 after acquiring an additional 259 shares during the period. Millstone Evans Group LLC purchased a new position in Revvity during the fourth quarter worth approximately $38,000. MassMutual Private Wealth & Trust FSB boosted its holdings in shares of Revvity by 55.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 385 shares of the company's stock valued at $43,000 after purchasing an additional 138 shares during the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of Revvity by 33.5% during the 4th quarter. EverSource Wealth Advisors LLC now owns 522 shares of the company's stock valued at $58,000 after buying an additional 131 shares during the period. Finally, GeoWealth Management LLC acquired a new stake in shares of Revvity during the 4th quarter worth $60,000. 86.65% of the stock is owned by hedge funds and other institutional investors.

Revvity Stock Down 0.9 %

RVTY traded down $0.83 on Friday, reaching $94.30. The company's stock had a trading volume of 1,390,004 shares, compared to its average volume of 914,162. Revvity, Inc. has a 1 year low of $88.53 and a 1 year high of $129.50. The business's 50 day moving average is $104.87 and its 200 day moving average is $113.03. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.60 and a quick ratio of 3.03. The stock has a market cap of $11.33 billion, a price-to-earnings ratio of 42.67, a price-to-earnings-growth ratio of 3.82 and a beta of 1.07.

Revvity (NYSE:RVTY - Get Free Report) last released its earnings results on Friday, January 31st. The company reported $1.42 EPS for the quarter, beating the consensus estimate of $1.37 by $0.05. Revvity had a return on equity of 7.68% and a net margin of 9.81%. During the same quarter in the previous year, the company posted $1.25 earnings per share. As a group, research analysts forecast that Revvity, Inc. will post 4.94 EPS for the current fiscal year.

Revvity Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, August 8th. Stockholders of record on Friday, July 18th will be given a $0.07 dividend. This represents a $0.28 annualized dividend and a dividend yield of 0.30%. The ex-dividend date is Friday, July 18th. Revvity's payout ratio is currently 12.67%.

Insider Activity

In other news, insider Joel S. Goldberg sold 15,170 shares of the business's stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $126.73, for a total value of $1,922,494.10. Following the completion of the sale, the insider now directly owns 33,400 shares in the company, valued at approximately $4,232,782. The trade was a 31.23 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.68% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on RVTY. KeyCorp boosted their price target on Revvity from $132.00 to $145.00 and gave the company an "overweight" rating in a research report on Monday, February 3rd. Robert W. Baird decreased their target price on Revvity from $141.00 to $127.00 and set an "outperform" rating for the company in a report on Monday, April 21st. Sanford C. Bernstein lowered shares of Revvity from an "outperform" rating to a "market perform" rating and set a $130.00 price target on the stock. in a report on Friday, January 10th. Raymond James reiterated an "outperform" rating and set a $145.00 price objective (up from $140.00) on shares of Revvity in a research note on Monday, February 3rd. Finally, Barclays cut their target price on shares of Revvity from $140.00 to $110.00 and set an "overweight" rating on the stock in a research note on Thursday, April 10th. Four investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $130.50.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.